Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing

Got story updates? Submit your updates here. ›

Amylyx Pharmaceuticals (NASDAQ:AMLX) co-CEO Justin Klee provided updates on the company's lead endocrine program, avexitide, and its pivotal LUCIDITY trial for post-bariatric hypoglycemia (PBH) during a presentation at the Leerink Partners Conference. Klee described avexitide as a 'first-in-class GLP-1 receptor antagonist' that the company believes can address the unmet need in PBH, a severe and debilitating condition with no approved treatments. He shared details on the LUCIDITY phase 3 trial, including its endpoints, enrollment status, and expectations around placebo response. Klee also discussed potential labeling considerations and the addressable patient population, as well as Amylyx's pipeline expansion plans for a long-acting GLP-1 antagonist and its program in Wolfram syndrome.

Why it matters

Avexitide represents a potential new treatment option for post-bariatric hypoglycemia, a serious condition that currently lacks any approved therapies. If successful in the LUCIDITY trial, avexitide could provide much-needed relief for the estimated 160,000 PBH patients in the U.S. who often struggle to manage severe and debilitating hypoglycemic episodes. The updates from Amylyx also highlight the company's broader pipeline strategy, including efforts to develop a long-acting GLP-1 antagonist and expand into other surgery-induced hypoglycemia conditions.

The details

Klee described avexitide as a 'first-in-class GLP-1 receptor antagonist' that competes with endogenous GLP-1. By blocking the GLP-1 receptor, avexitide lowers insulin and raises blood glucose, a mechanism the company believes is well-suited to conditions where the body overproduces GLP-1 and triggers hyperinsulinemic hypoglycemia. He highlighted post-bariatric hypoglycemia (PBH) as the most prevalent acquired cause of hyperinsulinemic hypoglycemia, estimating there are about 160,000 people in the U.S. with PBH. Klee said five prior trials of avexitide in PBH showed significant reductions in hypoglycemia and supported the FDA's Breakthrough Therapy designation for the program. The ongoing LUCIDITY phase 3 trial is designed as a 16-week randomized, placebo-controlled study with an open-label extension, and Klee said the company expects top-line results in the third quarter. He detailed how the trial defines and captures severe events, including Level II hypoglycemia (blood glucose <54 mg/dL) and Level III hypoglycemia (events requiring independent rescue). Klee also discussed potential labeling considerations, noting the trial is enrolling only patients with PBH following Roux-en-Y gastric bypass, and cited estimates suggesting this represents roughly 120,000 of the 160,000 U.S. PBH patients.

• Amylyx expects to report top-line results from the LUCIDITY phase 3 trial in the third quarter of 2026.

What they’re saying

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.